Abbott Laboratories Net Worth
Abbott Laboratories Net Worth Breakdown | ABT |
Abbott Laboratories Net Worth Analysis
Abbott Laboratories' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Abbott Laboratories' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Abbott Laboratories' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Abbott Laboratories' net worth analysis. One common approach is to calculate Abbott Laboratories' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Abbott Laboratories' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Abbott Laboratories' net worth. This approach calculates the present value of Abbott Laboratories' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Abbott Laboratories' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Abbott Laboratories' net worth. This involves comparing Abbott Laboratories' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Abbott Laboratories' net worth relative to its peers.
Enterprise Value |
|
To determine if Abbott Laboratories is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Abbott Laboratories' net worth research are outlined below:
| Abbott Laboratories has a strong financial position based on the latest SEC filings | |
| Over 78.0% of the company shares are held by institutions such as insurance companies | |
| On 15th of November 2024 Abbott Laboratories paid $ 0.55 per share dividend to its current shareholders | |
| Latest headline from zacks.com: Abbott Stock Declines While Market Improves Some Information for Investors |
Abbott Laboratories Quarterly Good Will |
|
Abbott Laboratories uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Abbott Laboratories. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Abbott Laboratories' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 17th of April 2024 Upcoming Quarterly Report | View | |
| 18th of July 2024 Next Financial Report | View | |
| 31st of March 2024 Next Fiscal Quarter End | View | |
| 22nd of January 2025 Next Fiscal Year End | View | |
| 31st of December 2023 Last Quarter Report | View | |
| 31st of December 2023 Last Financial Announcement | View |
Know Abbott Laboratories' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Abbott Laboratories is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Abbott Laboratories backward and forwards among themselves. Abbott Laboratories' institutional investor refers to the entity that pools money to purchase Abbott Laboratories' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Wells Fargo & Co | 2024-06-30 | 16.8 M | Jpmorgan Chase & Co | 2024-06-30 | 14.8 M | Legal & General Group Plc | 2024-06-30 | 14.3 M | Bank Of New York Mellon Corp | 2024-06-30 | 14.2 M | Polen Capital | 2024-09-30 | 13.9 M | State Farm Mutual Automobile Ins Co | 2024-09-30 | 13.6 M | Massachusetts Financial Services Company | 2024-09-30 | 13.3 M | Charles Schwab Investment Management Inc | 2024-09-30 | 12.6 M | Fisher Asset Management, Llc | 2024-09-30 | 11.1 M | Vanguard Group Inc | 2024-09-30 | 167.9 M | Blackrock Inc | 2024-06-30 | 131.1 M |
Follow Abbott Laboratories' market capitalization trends
The company currently falls under 'Mega-Cap' category with a total capitalization of 206.31 B.Market Cap |
|
Project Abbott Laboratories' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.14 | 0.17 | |
| Return On Capital Employed | 0.11 | 0.10 | |
| Return On Assets | 0.08 | 0.12 | |
| Return On Equity | 0.15 | 0.26 |
When accessing Abbott Laboratories' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Abbott Laboratories' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Abbott Laboratories' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Abbott Laboratories' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Abbott Laboratories. Check Abbott Laboratories' Beneish M Score to see the likelihood of Abbott Laboratories' management manipulating its earnings.
Evaluate Abbott Laboratories' management efficiency
Abbott Laboratories has Return on Asset of 0.0649 % which means that on every $100 spent on assets, it made $0.0649 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1484 %, implying that it generated $0.1484 on every 100 dollars invested. Abbott Laboratories' management efficiency ratios could be used to measure how well Abbott Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Abbott Laboratories' Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.12 in 2024, whereas Return On Capital Employed is likely to drop 0.10 in 2024. At this time, Abbott Laboratories' Non Current Liabilities Other is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 44.7 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 8.3 B in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 22.39 | 23.51 | |
| Tangible Book Value Per Share | 3.65 | 3.83 | |
| Enterprise Value Over EBITDA | 18.84 | 19.79 | |
| Price Book Value Ratio | 4.94 | 2.62 | |
| Enterprise Value Multiple | 18.84 | 19.79 | |
| Price Fair Value | 4.94 | 2.62 | |
| Enterprise Value | 179.9 B | 188.9 B |
Abbott Laboratories' management has consistently demonstrated strong leadership, driving both financial growth and operational excellence. By analyzing current market trends and future growth opportunities, we assess the stock's true value and potential for investors.
Enterprise Value Revenue 5.1724 | Revenue 41.2 B | Quarterly Revenue Growth 0.049 | Revenue Per Share 23.682 | Return On Equity 0.1484 |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Abbott Laboratories insiders, such as employees or executives, is commonly permitted as long as it does not rely on Abbott Laboratories' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Abbott Laboratories insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mccoy John A. Jr. over three months ago Disposition of tradable shares by Mccoy John A. Jr. of Abbott Laboratories at 113.27 subject to Rule 16b-3 | ||
Robert Alpern over three months ago Acquisition by Robert Alpern of tradable shares of Abbott Laboratories subject to Rule 16b-3 |
Abbott Laboratories Corporate Filings
8K | 15th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 31st of October 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F4 | 23rd of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 25th of June 2024 Other Reports | ViewVerify |
Abbott Laboratories Earnings per Share Projection vs Actual
Abbott Laboratories Corporate Directors
| Samuel Scott | Independent Director | Profile | |
| Phebe Novakovic | Independent Director | Profile | |
| Roxanne Austin | Independent Director | Profile | |
| Sally Blount | Independent Director | Profile |
Already Invested in Abbott Laboratories?
The danger of trading Abbott Laboratories is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Abbott Laboratories is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Abbott Laboratories. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Abbott Laboratories is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Abbott Stock Analysis
When running Abbott Laboratories' price analysis, check to measure Abbott Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abbott Laboratories is operating at the current time. Most of Abbott Laboratories' value examination focuses on studying past and present price action to predict the probability of Abbott Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abbott Laboratories' price. Additionally, you may evaluate how the addition of Abbott Laboratories to your portfolios can decrease your overall portfolio volatility.